Proteome Sciences stock analysis
Proteome Sciences (PI2) Stock Price & Analysis
PI2 Stock Chart & Stats
- Day’s Range
- EUR 0.01 - EUR 0.03
- 52-Week Range
- EUR 0.01 - EUR 0.04
- Previous Close
- EUR 0.01
- Volume
- N/A
- Average Volume (3M)
- 327
- Market Cap
- EUR 5.72M
- Enterprise Value
- EUR 20.50M
- Total Cash (Recent Filing)
- EUR 1.10M
- Total Debt (Recent Filing)
- EUR 15.95M
- Price to Earnings (P/E)
- ―
- Beta
- -4.85
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialized Proteomics Offering
The company operates in a specialized proteomics niche that directly supports drug discovery and biomedical research. Its combination of analytical services, mass spectrometry workflows, and bioinformatics gives it a defined offering for pharmaceutical, biotechnology, and academic customers over the medium term.
Improved Cash Flow Trend
Cash consumption improved materially in 2025 compared with the prior year, reducing the immediate pace of funding required by operations. Although cash flow remains negative, this improvement could support greater financial control if maintained through further cost discipline and operating stabilization.
Positive Reported EPS Growth
The reported positive EPS growth indicates that per-share earnings performance improved relative to the comparison period, providing one constructive signal within otherwise weak results. Sustaining this improvement would help demonstrate progress toward reducing losses, although the company remains unprofitable overall.
Bears Say
Severe Solvency Pressure
The combination of rising debt, deeply negative equity, and assets below total debt indicates a capital structure under significant strain. This reduces financial flexibility and leaves the company more exposed to refinancing requirements, potential dilution, and constraints on funding its operating plans.
Declining Revenue And Gross Profit
Revenue contraction alongside a move to negative gross profit points to deteriorating commercial scale and weak cost absorption. If this pattern persists, the company will have less operating leverage to support its specialized activities, making a return to sustainable profitability more difficult.
Persistent Operating Losses
Large operating and net losses over multiple years demonstrate that the current business model is not covering its cost base. Persistent unprofitability limits internally generated funding, increases reliance on external capital, and weakens the company’s ability to absorb further revenue or margin pressure.
Proteome Sciences News
PI2 FAQ
What was Proteome Sciences’s price range in the past 12 months?
What is Proteome Sciences’s market cap?
When is Proteome Sciences’s upcoming earnings report date?
How were Proteome Sciences’s earnings last quarter?
Is Proteome Sciences overvalued?
Does Proteome Sciences pay dividends?
What is Proteome Sciences’s EPS estimate?
How many shares outstanding does Proteome Sciences have?
What happened to Proteome Sciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Proteome Sciences?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Proteome Sciences
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Anil Wadhwani
- Employees
- 32
- Website
- www.proteomics.com
- Address
- Coveham House, Cobham, SU, KT11 3EP, GB
Proteome Sciences (PI2) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 6 | 0 |
| Technical Analysis | 3 | 6 | 0 |
| Moving Averages | 10 | 0 | 0 |








